I N VITRO AND IN VIVO EFFICACY OF INGAVIRIN ® AGAINST STRAINS OF PANDEMIC INFLUENZA VIRUS A(H1N1/09)V


Cite item

Full Text

Abstract

Aim. To study efficacy of Ingavirin ® i n vitro and in vivo against strains of pandemic influenza virus A(H1N1/09)v and influenza virus A(H5N1) and A(H3N2). Materials and methods. Changes in hemagglutinating and cytopathic activity of influenza virus strains A(H1N1/09)v, A(H5N1) and A(H3N2) during their incubation in the presence of Ingavirin ® or Remantadin ® on MDCK cell culture were studied. In mice infected by influenza strains A(H1N1/09)v and A(H3N2) and orally treated with Ingavirin ®, Tamiflu ® or Remantadin ® virus titers in lungs were measured. Results. There was decrease in hemagglutinating and cytopathic activity of influenza virus strains after incubation with Ingavirin ® in vitro . Ingavirin ® effectively inhibited reproduction of influenza virus strains A(H1N1/09)v and A(H3N2) in lungs of infected mice. Titers of these strains in lung homogenates decreased when Ingavirin ® was orally administered to infected mice. Conclusion. Strains of influenza virus A(H1N1/09)v were susceptible to Ingavirin ® and Tamiflu ® but resistant to Remantadin ®. Reference strains of A(H5N1) and A(H3N2) were susceptible to Ingavirin ®, Tamiflu ® and Remantadin ®.

Full Text

ЭФФЕКТИВНОСТЬ ИНГАВИРИНА ® IN VITRO И IN VIVO В ОТНОШЕНИИ ШТАММОВ ПАНДЕМИЧЕСКОГО ВИРУСА ГРИППА А(H1N1/09)V
×

About the authors

L. N Shishkina

State Scientific Center of Virology and Biotechno- logy «Vector», Koltsovo, Novosibirsk region

V. E Nebolsin

«Valenta Pharmazevtika», Ltd, Moscow, Russia

A. S Kabanov

State Scientific Center of Virology and Biotechno- logy «Vector», Koltsovo, Novosibirsk region

M. O Skarnovich

State Scientific Center of Virology and Biotechno- logy «Vector», Koltsovo, Novosibirsk region

N. A Mazurkova

State Scientific Center of Virology and Biotechno- logy «Vector», Koltsovo, Novosibirsk region

A. A Sergeev

State Scientific Center of Virology and Biotechno- logy «Vector», Koltsovo, Novosibirsk region

O. A Serova

State Scientific Center of Virology and Biotechno- logy «Vector», Koltsovo, Novosibirsk region

E. A Stavsky

State Scientific Center of Virology and Biotechno- logy «Vector», Koltsovo, Novosibirsk region

I. G Drozdov

State Scientific Center of Virology and Biotechno- logy «Vector», Koltsovo, Novosibirsk region

References

  1. Логинова С.Я., Борисевич С.В., Лыков М.В. и др. Изучение эффективности Ингавирина® in vitro в отношении «мексиканского» пандемического подтипа H1N1 вируса гриппа А, штаммы A/California/04/2009 и A/California/07/2009. Антибиот. химиотерап. 2009, 54 (3-4): 15-17.
  2. Пандемия гриппа (H1N1) — 2009: обзор ситуации в Европейском регионе ВОЗ. http://www.euro.who.int/influenza/AH1N1/ 2009.
  3. Пандемический грипп (H1N1) — 2009, Украина. http://www.who.int/csr/don/2009_11_01/ru/index.html.
  4. Руководство по содержанию и использованию лабораторных животных. Washington, D.C., National Academy Press, 1996.
  5. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. Р.У.Хабриев (ред.). М., Медицина, 2005.
  6. Снижение уровня пандемического гриппа в Европе 01-07 февраля 2010. http://www. euro.who.int/influenza/AH1N1/2010.
  7. WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and other Influenza Viruses 20 August 2009. http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Shishkina L.N., Nebolsin V.E., Kabanov A.S., Skarnovich M.O., Mazurkova N.A., Sergeev A.A., Serova O.A., Stavsky E.A., Drozdov I.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies